Annals of Surgical Oncology Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Han, N. M.
Right arrow Articles by Gallick, G. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Han, N. M.
Right arrow Articles by Gallick, G. E.

Annals of Surgical Oncology, Vol 4, Issue 3 264-268, Copyright © 1997 by Society of Surgical Oncology

ARTICLES

Overexpression of focal adhesion kinase (p125FAK) in human colorectal carcinoma liver metastases: independence from c-src or c-yes activation

N. M. Han, R. Y. Fleming, S. A. Curley and G. E. Gallick
Department of Surgery, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.

BACKGROUND: p125FAK, pp60C-src, and pp62c-yes are protein tyrosine kinases that function in signaling pathways regulating cell adhesion, migration, and growth. The expression and tyrosine kinase activities of pp60c-src and pp62c-yes, and the expression of p125FAK are increased in colorectal tumor metastases relative to normal mucosa. This study investigates whether differences in the activation of pp60c-src and pp62c-yes in colorectal liver metastases correlated with differences in p125FAK expression and whether prognostic significance could be demonstrated from the extent of expression of p125FAK in metastases. METHODS: Activities of pp60c-src and pp62c-yes were measured in the immune complex kinase assay. Relative levels of p125FAK, pp60c-src, and pp62c-yes were determined by immunoblotting. RESULTS: p125FAK was overexpressed in 29 of 30 colorectal cancer liver metastases (range of two-to 195-fold increase compared with normal mucosa). The degree of overexpression of p125FAK was not a significant prognostic factor in survival. A differential activation of pp60c-src and pp62c-yes in colorectal carcinoma liver metastases was observed. However, overexpression of p125FAK was observed in metastases with either pp60c-src or pp62c-yes activated in colorectal carcinoma liver metastases. CONCLUSIONS: p125FAK overexpression appears to be a marker present in colorectal cancer cells with a metastatic phenotype. Furthermore, p125FAK overexpression is independent of pp60c-src or pp62c-yes activation in human colorectal carcinoma liver metastases.


This article has been cited by other articles:


Home page
 Cancer Res.Home page
J. Halder, Y. G. Lin, W. M. Merritt, W. A. Spannuth, A. M. Nick, T. Honda, A. A. Kamat, L. Y. Han, T. J. Kim, C. Lu, et al.
Therapeutic Efficacy of a Novel Focal Adhesion Kinase Inhibitor TAE226 in Ovarian Carcinoma
Cancer Res., November 15, 2007; 67(22): 10976 - 10983.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Halder, A. A. Kamat, C. N. Landen Jr., L. Y. Han, S. K. Lutgendorf, Y. G. Lin, W. M. Merritt, N. B. Jennings, A. Chavez-Reyes, R. L. Coleman, et al.
Focal Adhesion Kinase Targeting Using In vivo Short Interfering RNA Delivery in Neutral Liposomes for Ovarian Carcinoma Therapy.
Clin. Cancer Res., August 15, 2006; 12(16): 4916 - 4924.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. R. Hess, L.-M. Postovit, N. V. Margaryan, E. A. Seftor, G. B. Schneider, R. E.B. Seftor, B. J. Nickoloff, and M. J.C. Hendrix
Focal Adhesion Kinase Promotes the Aggressive Melanoma Phenotype
Cancer Res., November 1, 2005; 65(21): 9851 - 9860.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
A. K. Sood, J. E. Coffin, G. B. Schneider, M. S. Fletcher, B. R. DeYoung, L. M. Gruman, D. M. Gershenson, M. D. Schaller, and M. J.C. Hendrix
Biological Significance of Focal Adhesion Kinase in Ovarian Cancer: Role in Migration and Invasion
Am. J. Pathol., October 1, 2004; 165(4): 1087 - 1095.
[Abstract] [Full Text] [PDF]

Home page
 J. Histochem. Cytochem.Home page
K. A. Matkowskyj, K. Keller, S. Glover, L. Kornberg, R. Tran-Son-Tay, and R. V. Benya
Expression of GRP and Its Receptor in Well-differentiated Colon Cancer Cells Correlates with the Presence of Focal Adhesion Kinase Phosphorylated at Tyrosines 397 and 407
J. Histochem. Cytochem., August 1, 2003; 51(8): 1041 - 1048.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
V. M. Golubovskaya, S. Gross, A. S. Kaur, R. I. Wilson, L.-H. Xu, X. H. Yang, and W. G. Cance
Simultaneous Inhibition of Focal Adhesion Kinase and Src Enhances Detachment and Apoptosis in Colon Cancer Cell Lines
Mol. Cancer Res., August 1, 2003; 1(10): 755 - 764.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. L. Lark, C. A. Livasy, B. Calvo, L. Caskey, D. T. Moore, X. Yang, and W. G. Cance
Overexpression of Focal Adhesion Kinase in Primary Colorectal Carcinomas and Colorectal Liver Metastases: Immunohistochemistry and Real-Time PCR Analyses
Clin. Cancer Res., January 1, 2003; 9(1): 215 - 222.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. G. Cance, J. E. Harris, M. V. Iacocca, E. Roche, X. Yang, J. Chang, S. Simkins, and L. Xu
Immunohistochemical Analyses of Focal Adhesion Kinase Expression in Benign and Malignant Human Breast and Colon Tissues: Correlation with Preinvasive and Invasive Phenotypes
Clin. Cancer Res., June 1, 2000; 6(6): 2417 - 2423.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
L.-H. Xu, X. Yang, C. A. Bradham, D. A. Brenner, A. S. Baldwin Jr., R. J. Craven, and W. G. Cance
The Focal Adhesion Kinase Suppresses Transformation-associated, Anchorage-independent Apoptosis in Human Breast Cancer Cells. INVOLVEMENT OF DEATH RECEPTOR-RELATED SIGNALING PATHWAYS
J. Biol. Chem., September 22, 2000; 275(39): 30597 - 30604.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the Society of Surgical Oncology.